Tech Company Financing Transactions
Intercept Pharmaceuticals Funding Round
Intercept Pharmaceuticals closed a $21.8 million financing round on 6/30/2006. Investors included Rally Ventures and private investors.
Transaction Overview
Company Name
Announced On
6/30/2006
Transaction Type
Venture Equity
Amount
$21,800,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10 Hudson Yards 37th Floor
New York, NY 10001
USA
New York, NY 10001
USA
Phone
Undisclosed
Website
Email Address
Overview
For 11 years, Intercept has researched and developed a novel nuclear receptor (FXR). Find out how this science applies to liver and metabolic conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Pruzanski
Chief Financial Officer
Sandip Kapadia
Chief Operating Officer
Jerome Durso
President
Lisa Bright
VP - General Counsel
Ryan Sullivan
VP - Human Resources
David Ford
VP - R & D
Christian Weyer
Browse more venture capital transactions:
Prev: 6/30/2006: MetroFi venture capital transaction
Next: 6/30/2006: Kona Bay Marine Resources venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs